ESC Digital & AI Summit 2026
This is exactly the conversation Powerful Medical is built for. Our team will be in Basel to present and discuss the science behind PMcardio and to connect with the community shaping the future of AI in cardiovascular care.
Basel, Switzerland
November 12–13, 2026
The ESC Digital & AI Summit is the European Society of Cardiology's dedicated meeting for the people who build and implement digital health and AI solutions in cardiology. Following a successful first edition, the 2026 summit again offers a small, focused, human-scale setting for engineers, data scientists, digital health innovators and forward-thinking clinicians.
Across two immersive days, the programme goes deep into architectures, algorithms, data quality, validation, workflow integration and real-world impact. Sessions are highly interactive and technically rigorous, combining cutting-edge science with concrete use cases and live discussion of regulatory and ethical questions — with the stated goal of co-designing trustworthy, explainable AI that clinicians can confidently use and health systems can safely adopt.
- Venue: Basel, Switzerland
- Organiser: European Society of Cardiology (ESC)
- Website: escardio.org
Share this article
About PMcardio
PMcardio features FDA-authorized and CE-marked AI ECG models that interpret any 12-lead ECG — from a photo or a digital file — in seconds. It detects 50+ ECG findings, including occlusion myocardial infarction (OMI) — the acute coronary occlusions that conventional STEMI criteria miss in over half of cases. Its Queen of Hearts™ OMI model holds FDA Breakthrough Device Designation, and PMcardio is already used by 100,000+ clinicians who have analyzed more than 2.5 million ECGs.
About Powerful Medical
Powerful Medical is a medical-technology company using artificial intelligence to transform how cardiovascular disease — the world’s leading cause of death — is diagnosed. Founded in 2017, it built PMcardio, the world’s first AI medical device to detect acute coronary occlusion (OMI) from an ECG. Its research is published in the European Heart Journal – Digital Health and validated across 25+ clinical studies, and its Queen of Hearts™ model earned FDA Breakthrough Device Designation. To date, PMcardio has supported the detection of 120,000+ heart attacks across 150+ hospital deployments worldwide.